Your browser doesn't support javascript.
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.
Dhama, Kuldeep; Dhawan, Manish; Tiwari, Ruchi; Emran, Talha Bin; Mitra, Saikat; Rabaan, Ali A; Alhumaid, Saad; Alawi, Zainab Al; Al Mutair, Abbas.
  • Dhama K; Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India.
  • Dhawan M; Department of Microbiology, Punjab Agricultural University, Ludhiana, India.
  • Tiwari R; The Trafford Group of Colleges, Manchester, UK.
  • Emran TB; Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, Uttar Pradesh Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vigyan Vishwavidyalaya Evam Go Anusandhan Sansthan (DUVASU), Mathura, India.
  • Mitra S; Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, India.
  • Rabaan AA; Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh.
  • Alhumaid S; Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka, Bangladesh.
  • Alawi ZA; Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
  • Al Mutair A; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Hum Vaccin Immunother ; 18(5): 2045853, 2022 11 30.
Article in English | MEDLINE | ID: covidwho-1730554
ABSTRACT
Multiple vaccines have recently been developed, and almost all the countries are presently vaccinating their population to tackle the COVID-19 pandemic. Most of the COVID-19 vaccines in use are administered via intramuscular (IM) injection, eliciting protective humor and cellular immunity. COVID-19 intranasal (IN) vaccines are also being developed that have shown promising ability to induce a significant amount of antibody-mediated immune response and a robust cell-mediated immunity as well as hold the added ability to stimulate protective mucosal immunity along with the additional advantage of the ease of administration as compared to IM injected vaccines. By inducing secretory IgA antibody responses specifically in the nasal compartment, the intranasal SARS-CoV-2 vaccine can prevent virus infection, replication, shedding, and disease development, as well as possibly limits virus transmission. This article highlights the current progress, advantages, prospects, and challenges in developing intranasal COVID-19 vaccines for countering the ongoing pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Hum Vaccin Immunother Year: 2022 Document Type: Article Affiliation country: 21645515.2022.2045853

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Hum Vaccin Immunother Year: 2022 Document Type: Article Affiliation country: 21645515.2022.2045853